ClinicalTrials.gg
RecruitingNCT06905301IMPULSEUpdated May 5, 2026

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

An observational study in Breast Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 7 sites in Russia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know · 6 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 200 studies in Breast Neoplasms by Novartis — 17 open to participants now, 31 under way, 4 of them phase 3. Breast Neoplasms · Novartis.

Planned enrollment
31st of 39
240 · median 595
Started
2026
with 10 others
Observational
39 of 200
8 open now
Primary completion
2029-12
later than 20 of 30 live
Registered
178th of 200
by date

Among the 200 studies in Breast Neoplasms by Novartis, this one is the 31st largest by planned enrollment of the 39 observational ones that give a count, is one of 11 that started in 2026, is one of 39 observational ones, reaches primary completion later than 20 of the 30 other live ones, and was the 178th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 200 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor (AI). The purpose of the app is to increase adherence to treatment by informing patients about the risks of relapse and adverse event prevention and treatment.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with HR+ HER2- stage II-III breast cancer who have started treatment with ribociclib + AI (± GnRH agonist for premenopausal men and women) will be enrolled in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female and male patients with verified and radically treated stage II-III hormone receptor positive -negative breast cancer;
  2. Age ≥ 18 at the time of initiation of ribociclib therapy;
  3. Patients who were prescribed ribociclib + AI (±GnRH agonist for premenopausal men and women) not earlier than 28 days before signing the ;
  4. It is allowed to start hormone therapy with AI (±GnRH agonist) not earlier than 12 months before the start of ribociclib;
  5. Provision of written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients participating in any interventional clinical study at the time of signing the ;
  2. Patients receiving active treatment for malignant neoplasms other than BC at the time of enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Using Application

    HR + HER2- BC patients receiving adjuvant ribociclib + AI therapy in routine clinical practice that use the web application

    Drug: Ribociclib · Drug: Letrozole · Drug: Anastrozole

  • Non using Application

    HR + HER2- BC patients receiving adjuvant ribociclib + AI therapy in routine clinical practice that do not use the web application

    Drug: Ribociclib · Drug: Letrozole · Drug: Anastrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Number (%) of patients who remain on treatment with ribociclib + AI over the 12 months period

    The difference between the two groups (App and non-App) in number (%) of patients who remain on treatment with ribociclib + AI over the 12 months period (excluding patients who discontinued treatment due to AE, disease relapse, or death)

    Time frame: 12 months

Secondary outcomes

  1. Number of sessions using the web application per month

    To describe the rate of the web application usage in the group of patients who use the web application.

    Time frame: Month 1 - Month 36

  2. Total duration of sessions (in minutes) per month

    To describe the rate of the web application usage in the group of patients who use the web application.

    Time frame: Month 1 - Month 36

  3. Number of questions to the chatbot per month

    To describe the rate of the web application usage in the group of patients who use the web application.

    Time frame: Month 1 - Month 36

  4. Evaluation of patient satisfaction with the application on a 0-10 visual analog scale (VAS)

    Evaluation of patient satisfaction with the application on a 0-10 VAS, where 0 is for completely dissatisfied, 10 is for completely satisfied in M1, M3, M6, M12, M24, M36

    Time frame: Month 1, 3, 6, 12, 24, 36

  5. Evaluation of oncologist satisfaction with the application according to a 0-10 VAS

    Evaluation of oncologist satisfaction with the application according to a 0-10 VAS, where 0 is for completely dissatisfied, 10 is for completely satisfied in M1, M3, M6, M12, M24, M36

    Time frame: Month 1, 3, 6, 12, 24, 36

  6. Number of patients in each response category according to the questionnaire on quality of life

    The number (%) of patients in each response category (no problems, mild problems, moderate problems, severe problems, and extremely severe problems) according to the questionnaire scale (mobility, self-care, normal activities, pain/discomfort, anxiety/depression) in M1, M3, M6, M12, M24, M36 in the groups using and not using the web application

    Time frame: Month 1, 3, 6, 12, 24, 36

  7. VAS score according to the questionnaire on quality of life

    VAS score according to the questionnaire (VAS 0-100, where 0 is the worst health state and 100 is the best health state) at M1, M3, M6, M12, M24, and M36 in both app user and non-app user groups

    Time frame: Month 1, 3, 6, 12, 24, 36

  8. Assessment of patient satisfaction with treatment

    Assessment of patient satisfaction with treatment (VAS 0-10, where 0 is completely dissatisfied, and 10 is completely satisfied) at M3, M6, M12, M24, and M36 in both app user and non-app user groups

    Time frame: Month 3, 6, 12, 24, 36

  9. Dose intensity

    Dose intensity (% of missed doses as assessed by the patient, except for therapy suspension due to AE) at M3, M6, M12, M24, and M36 in both app user and non-app user groups

    Time frame: Month 3, 6, 12, 24, 36

  10. Number of patients with adverse events (AE)

    The percentage (%) of patients with AE (cumulative and depending on the severity) at M3, M6, M12, M24, and M36 in both app user and non-app user groups

    Time frame: Month 3, 6, 12, 24, 36

  11. Number of patients with dose reduction and/or discontinuation of ribociclib therapy due to progression, death for breast cancer, death from another cause, other AE

    The percentage (%) of patients with dose reduction and/or discontinuation of ribociclib therapy due to progression, death for breast cancer, death from another cause, other AE at M3, M6, M12, M24, and M36 in both app user and non-app user groups

    Time frame: Month 3, 6, 12, 24, 36

  12. Number of patients by age, education, occupation, TNM (tumor, nodus, metastasis) stage, tumor grade (G), Ki67 level in both app user and non-app user groups

    Proportion (%) of patients by age, education, occupation, TNM (tumor, nodus, metastasis) stage, tumor grade (G), Ki67 level in both app user and non-app user groups

    Time frame: Baseline

07

Study locations

7 of 7 sites recruiting
  • Novartis Investigative Site
    Pskov, Russia 180000, Russia
    Recruiting
  • Novartis Investigative Site
    Moscow, 115304, Russia
    Recruiting
  • Novartis Investigative Site
    Saint Petersburg, 194017, Russia
    Recruiting
  • Novartis Investigative Site
    Saint Petersburg, 194291, Russia
    Recruiting
  • Novartis Investigative Site
    Saint Petersburg, 197758, Russia
    Recruiting
  • Novartis Investigative Site
    Sestroretsk, 197706, Russia
    Recruiting
  • Novartis Investigative Site
    Ufa, 450054, Russia
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.

Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 47 months is close to that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 1, 2025
StartActual
Jan 23, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06905301
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
Jan 23, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 5, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion